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They are effective in the treatment of candidaemia, esophaegeal
candidaisis, and aspergillus infections. Selected agents can also
be used for prophylaxis in stem cell transplant recipients and
other candida infections. Currently, there are 3 echinocandins
available, caspofungin, micafungin and anidulafungin. No dosage
adjustment is required for renal impairment. Only caspofun-
gin requires adjustment in liver insufﬁciency. Pharmacokinetic-
pharmacodynamic studies have identiﬁed that these agents are
concentration dependent with post-antifungal effect. Therefore
a single daily dosing regimen is usually sufﬁcient. In addition,
novel dosing regimen such as extended interval dosing (alternate
day or even weekly) may be possible as demonstrated in animal
models. While these agents have demonstrated similar efﬁcacy,
patients’ comfort would be another considerations in the choice
of anti-infective agents. Possibility on extended interval dosing,
and drug cost would impact on the hospital decision on their
formulary placement.
Concurrent Session 4 – HCV Development and
Strategies
CS4-01 Response-guided Therapy for Chronic Hepatitis C
Stefan Zeuzem*. Professor of Medicine, Chief, Department of
Medicine, Goethe University Hospital, Frankfurt a.M., Germany
Pegylated interferon alfa in combination with ribavirin admin-
istered for 48 and 24 weeks has been approved as standard
antiviral treatment in patients with HCV genotype 1 (4-6) and
2/3 infection, respectively, in many countries. Different virus-
and host-related baseline parameters are known to predict
the probability of sustained virologic response including HCV
genotype, HCV viral load, gamma glutamyltranspeptidase (GGT)
levels, age and liver ﬁbrosis. While HCV genotype 2, 3 infected
patients are generally treated for 24 weeks, management of
therapy is based on early discontinuation rules in HCV genotype
1 infected patients with a low or no chance of further sustained
virologic response. Thereby, a decline of less than 2 log10 steps
at week 12 in comparison with baseline (early virologic response,
EVR) and detectable HCV RNA at week 24 by a sensitive assay
(detection limit ≤50 IU/ml) can be safely used as stopping rules
with predictive values of 98-100% for virologic non-response. Fu-
ture developments are aiming for individualization of treatment
duration based on HCV RNA concentrations before initiation
of therapy and decline early during therapy. Rapid virologic
response (RVR) deﬁned as undetectable HCV RNA at week 4
of therapy (≤50 IU/ml) together with low baseline viral load
(≤600.000 IU/ml) were introduced as parameters for shortening
of treatment duration in HCV genotype 1 infected patients with-
out a loss of the probability of sustained virologic response. Vice
versa in patients with a slow virologic response which become
HCV RNA negative at the ﬁrst time at week 24 of therapy prolon-
gation of treatment duration to 72 weeks seems to be associated
with increased sustained virologic response rates. Similar in HCV
genotype 2, 3 infected patients reduction of treatment duration
from 24 to 12-16 weeks was investigated in different clinical
trials. However, in several studies shortening therapy to 12-16
weeks higher relapse rates were reported and future trials are
needed to deﬁne subgroups of patients with speciﬁc baseline
parameters (e.g. genotype, viral load, degree of ﬁbrosis) and
RVR at week 4 for a safe reduction of treatment duration.
Basic to the development of new speciﬁc anti-HCV drugs is the
understanding of the viral life cycle, in particular the genomic or-
ganization and the polyprotein processing. Major progress in this
ﬁeld was achieved due to the development of sub-genomic and
more recently full-genomic replicon systems. The HCV genome
is a single-stranded RNA molecule that contains a single open
reading frame encoding a polyprotein of about 3000 amino acids.
The polyprotein is subsequently processed at the level of the
endoplasmic reticulum (ER) by cellular and viral proteases to
yield 4 structural and 6 non-structural proteins. The open read-
ing frame is ﬂanked by 5’ and 3’ untranslated regions. Each
single HCV structure represents a potential antiviral target. An-
tisense oligonucleotides, ribozymes, siRNA, and small molecules
have been targeted in particular against the 5’-noncoding region
with substantial success in vitro but not yet in vivo. Inhibition
of nucleocapsid formation to the icosahedral viral coat is an
attractive target, however, no speciﬁc molecules have yet been
developed. Envelope proteins HCV E1 and E2 are the basis for the
development of prophylactic and/or therapeutic vaccines.
NS3 and NS4A are cleaved by the catalytic activity of the NS3
protease domain. In addition to the protease domain located in
the 189 aminoterminal amino acids, NS3 also possesses a helicase
domain located in the 442 carboxyterminal amino acids. The
NS3 protease domain is responsible to complete the polyprotein
processing down to NS4B, NS5A, and NS5B. Despite the fact that
the catalytic site is a shallow and largely hydrophobic groove and
therefore very difﬁcult to target several compounds have been
successfully designed (BILN 2061, VX-950, SCH503034, etc.). The
NS5B RNA-dependent RNA polymerase is the key enzyme for syn-
thesis of a complementary minus-strand RNA using the genome as
template, and the subsequent synthesis of genomic plus-strand
RNA from this minus-strand RNA template. The active site of
the enzyme is a target for nucleoside/nucleotide analogue in-
hibitors. Nonnucleoside inhibitors, reported to bind at various
sites, may act by blocking the enzyme in the initiation mode
through inhibition of a conformational change needed to proceed
with elongation.
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Hepatitis C virus (HCV) affects an estimated 175 million people
worldwide. Up to 4 million people will be newly infected each
year, and the majority of these will progress to chronic infec-
tion. There are currently six major genotypes, with geographical
differences in the distribution of these different genotypes. In
China, the predominant genotypes are 1b and 2a, compared to
Hong Kong, where the predominant genotypes are 1b and 6.
The most important clinical implication of HCV genotypes lies
in the differences in response to antiviral therapy between the
different genotypes, and HCV genotypes is the strongest pre-
dictor of treatment response. Therefore, the determination of
HCV genotype has become an essential part in the treatment of
chronic hepatitis C. The exact mechanism of why some geno-
types are more difﬁcult to treat than others remains unknown,
and is likely to involve both host and viral factors. With our
current knowledge, patients infected with genotype 1 and 4 have
an inferior response to interferon-based therapy compared to
patients with genotypes 2, 3, 5 and 6.
CS4-03 Mechanism of IFN-gamma in Anti-HCV Infection
Xuefan Bai *. Department of Infectious Diseases, Tangdu
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CS4-04 The Impact of Lipid Proﬁles on HCV RNA Levels in
Patients with Genotypes 1 and 2
Chen-Hua Liu*. Department of Internal Medicine, National
Taiwan University Hospital, Taipei, Taiwan
Chronic hepatitis C virus (HCV) infection, a leading cause of cir-
rhosis, hepatocellular carcinoma (HCC) and liver failure, affects
more than 170 million people worldwide. Despite the improving
